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comparator before entering negotiations. The negotiated price was between 0% and 
56% lower compared to the price listed in the AMNOG dossier, regardless of the level 
of additional benefit. The number of eligible patients for each drug (141 - 214,000) 
tends to correlate with the negotiated rebate. ConClusions: An additional benefit 
is necessary for a reimbursement beyond the reference group price. Despite the 
small number of observations it might be concluded, that the reimbursed price 
inversely correlates with disease incidence. The highest rebate on reimbursement 
price resulted from the decision of the arbitration board.
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fInAncIng mecHAnIsms
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objeCtives: Budget impact analysis is the traditional approach of assessing the 
affordability of new interventions. While vaccination has been shown to be one of 
the most cost-effective means to improve health, budget requirements can be a 
barrier. This study aims at comparing an affordability indicator of a new vaccine in 
countries with similar Gross Domestic Product (GDP) per capita, but different health 
care financing mechanisms. Methods: Based on National Health Accounts data, 
analyses of Total Health Expenditures (THE) and share of Public Health Expenditures 
(PHE) of various middle income countries were performed. Brazil and Turkey were 
selected for in-depth analysis as they had comparable GDPs and health care 
expenditures per capita. Health care access and financing data were also obtained 
from various government sources for a quantitative analysis. The budget require-
ments for a new vaccine costing $40 Purchasing Power Parity (PPP) per immunized 
child covering 80% of the birth cohort were calculated and expressed as a share of 
PHE. Results: THE per capita doubled over 10 years in both countries since 2001, 
reaching $1,037 (PPP) for Brazil and $1,160 for Turkey in 2011. However, the share of 
PHE is vastly different; 46% in Brazil compared to 75% in Turkey. Implementing the 
new vaccine would require an additional budget of $97Million and $42Million. While 
large in absolute values they represent only 0.11% of the PHE in Brazil and 0.07% in 
Turkey. The higher affordability in Turkey can be explained by a different financing 
mechanism. ConClusions: While the implementation of a new vaccine in com-
parable countries in terms of wealth and THE per capita would require significant 
additional national spending in absolute terms, it represents only a small fraction 
of the PHE. The underlying health care financing mechanisms is an important factor 
affecting the affordability of a new vaccination program.
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IQwIg’s effIcIency frontIer APProAcH: fIt for PurPose!
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objeCtives: Since its adoption by the Institute for Quality and Efficiency in Health 
Care (IQWiG) in 2009, the Efficiency Frontier (EF) approach is criticized by the phar-
maceutical industry, key opinion leaders and national organizations. In a German 
context, we aim to verify the accuracy of those concerns. Methods: Review of the 
most commonly stated arguments against the EF-approach published within the 
scientific community and given as stakeholders’ response on IQWiG’s first cost-
effectiveness analysis of antidepressants. Results: Often stated objections against 
the EF include: 1) no international health economic standard, 2) merely disease 
specific without prioritization across disease areas, 3) no fixed threshold, and 4) 
avoiding the quality-adjusted life year (QALY). Ad 1): IQWiG adopted the EF-approach 
to inform setting appropriate reimbursement caps (since 2011 to inform negotia-
tions for appropriate reimbursement caps with an interquartile-range as basis). 
In other jurisdictions, an appropriate price need not be determined; decisions (or 
recommendations) are made regarding whether or not the cost-effectiveness of 
a drug supports (restricted) reimbursement. Ad 2+3): Although prioritizing funds 
is no primary aim in Germany, the EF can still be applied equally across indica-
tions. Within indications, the reimbursement cap may not distort competition by 
disadvantaging a manufacturer unfairly and needs to be appropriate when com-
pared with other available interventions. Contrary to the EF-approach, determining 
prices based on arbitrary fixed thresholds may not stand up in court. Ad 4): Despite 
methodological doubts concerning QALYs, they are not antecedently excluded as 
possible patient-relevant outcome measure when using the EF in Germany. Only 
a fixed cost/QALY-threshold was rejected. ConClusions: The EF fits the purpose 
of decision-making in Germany. Most objections are flawed or originate from a 
profound misunderstanding of the concept or the German (legal) context, where 
the EF is necessary and viable. The EF’s prime distinction remains: Deriving flexible, 
non-arbitrary thresholds for disease areas.
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objeCtives: A diagnostic test is any kind of medical test performed to aid in the 
diagnosis or detection of disease and is becoming a key component of Personalized 
Health Care (PHC). The market access and reimbursement pathways for pharmaceu-
ticals are well described however such pathways are missing for diagnostics in many 
countries and similarities between countries are not well understood. Methods: A 
targeted literature review has been executed on top of reviews from market access 
and reimbursement authorities in Germany, the UK and the US. Existing pathways 
were plotted and key decision criteria have been evaluated in terms of comparability 
and health care decison-maker impact. Results: In Germany inpatient reimburse-
ment is being differentiated from outpatient with inpatient access being easier to be 
achieved (DRG, OPS coding). The outpatient pathway includes a full evidence pack-
signs that a potential discount had lowered a list price in one of the other countries, 
but is it clear that despite the external reference price systems in Europe prices of 
high-priced therapies vary considerably.
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objeCtives: To elicit public preference for drug reimbursement criteria in Korea’s 
universal health insurance system using three commonly used weighting methods 
in Multi-Criteria Decision-Analysis (MCDA). Methods: Based on literature review, 
we established five criteria in drugs reimbursement decision-making: disease 
impacts, context of reimbursement, improvement of health outcomes, economics 
and quality of evidence. We evaluated the relative importance of five criteria using 
three weighting methods of direct rating (DR), SWING and analytic hierarchy process 
(AHP). 283 people were selected across the country by quota sampling and asked to 
assess the weights of five criteria with all three weighting methods repeatedly. The 
survey was self-administered by the participants with help of the trained interview-
ers. Results: It was revealed that improvement of health outcomes and disease 
impacts have relatively higher weights than other three criteria in all weighting 
methods. Survey participants considered improvement of health outcomes the 
most important with DR (Mean [SD]: 0.210 [0.033]) and AHP (0.271 [0.127]), whereas 
disease impacts with SWING (0.231 [0.050]). Meanwhile, no coherence was shown 
in the low-ranked three criteria (context of reimbursement, economics, and quality 
of evidence) over three weighting methods. Quality of evidence ranked the third 
with DR (0.200 [0.035]), the fifth with SWING (0.165 [0.041]) and the fourth with AHP 
(0.160 [0.121]). Economics ranked the fourth with DR (0.197 [0.035]) and the third 
with SWING (0.192 [0.045]) and AHP (0.207 [0.118]). Lastly, context of reimbursement 
ranked the fifth with DR (0.188 [0.035]) and AHP (0.112 [0.090]) and the fourth with 
SWING (0.189 [0.045]). ConClusions: In this study, it was discovered that the sur-
vey participants considered improvement of health outcomes and disease impacts 
relatively more important than economics, context of reimbursement and quality 
of evidence in drug reimbursement decision making.
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objeCtives: This study explores current applications (and potential future use) 
of the Efficiency Frontier (EF) in health economic evaluation. Methods: We per-
formed desk research on pharmacoeconomic guidelines for current usage of the 
EF and investigated possibilities for future use. Results: Currently, the EF is offi-
cially used in 3 European countries. In Germany, since the enforcement of the ‘Act 
on the Reform of the Market for Medicinal Products’ (AMNOG) in January 2011, 
IQWiG applies the EF to determine non-arbitrary flexible thresholds across disease 
areas to ultimately determine an appropriate reimbursement price of new drugs 
(including interquartile-range to display uncertainty) in negotiations on request of 
the decision maker or manufacturer. In Belgium, the updated KCE guidelines dated 
July 2012 request the EF to identify the appropriate comparator among all relevant 
alternatives. In France, the updated HAS guidelines dated October 2012 require 
health interventions to be plotted on the EF to inform decision-making. In the 
future, the EF-approach could also be used to check on prices of national reference 
pricing clusters. Furthermore, the EF could help with priority setting (as suggested 
by the World Health Organization guide to cost-effectiveness analysis in 2003) and 
guiding or informing potential future (dis)investment decisions. The EF may also be 
combined with other approaches (e.g. making reimbursement decisions up to an 
ex ante fixed cost/outcome-threshold but setting prices beyond that level with the 
flexible EF). Lastly, it should not be overlooked that the EF can be applied for multiple 
purposes simultaneously. ConClusions: Since its first use to measure hospital 
efficiency, the EF is a valuable tool in health economics. Currently, its use diffuses 
within health economic evaluation and reimbursement decision-making. Yet, the 
full potential of the approach has not been exploited so far and the EF-approach 
remains under-researched by the scientific community.
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correlAtIon of rebAte?
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LASER Analytica, Loerrach, Germany
objeCtives: In January 2011 the new German law on the reorganization of the 
pharmaceutical market (AMNOG) came into force with the intention to reduce drug 
prices in Germany. Up to June 2013 44 dossiers completely evaluated and for 16 drugs 
(excluding orphan drugs) a price has been negotiated between the manufacturer and 
the National Association of Statutory Health Insurance Funds (GKV-SV). Since previ-
ous analyses have shown no correlation of negotiated price and the extent of clinical 
benefit, the underlying analysis aims to identify further parameters potentially 
influencing the reimbursed price of a new drug. Methods: Evaluated drugs with 
completed price negotiation between manufacturers and the GKV-SV were selected 
from the website of the Federal Joint Committee (G-BA). The manufacturer free 
price was analyzed for potential interactions with following parameters extracted 
from module 3 of the AMNOG dossier: number of eligible patients, annual drug cost 
of the evaluated intervention and appropriate comparator, and the final price as 
listed in the Lauer-Taxe (official German drug price index). Results: The 16 drugs, 
for which a negotiated reimbursement price was available, showed a minor (n= 8), 
considerable (n= 5), not quantifiable (n= 2) or no additional clinical benefit (n= 1).The 
investigated drug price was between 0,73 and 71 times the price of its appropriate 
